Cargando…

Lupus-associated atypical memory B cells are mTORC1-hyperactivated and functionally dysregulated

OBJECTIVES: A population of atypical memory B cells (AtMs) are greatly expanded in patients with active lupus, but their generation and pathophysiological roles are poorly defined. The aim of this study was to comprehensively characterise lupus AtMs with a purpose to identify therapeutic clues to ta...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Chunmei, Fu, Qiong, Guo, Qiang, Chen, Sheng, Goswami, Shyamal, Sun, Shuhui, Li, Teng, Cao, Xingjian, Chu, Fuying, Chen, Zechuan, Liu, Mei, Liu, Yuanhua, Fu, Ting, Hao, Pei, Hao, Yi, Shen, Nan, Bao, Chunde, Zhang, Xiaoming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2019
Materias:	Systemic Lupus Erythematosus
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6691860/ https://www.ncbi.nlm.nih.gov/pubmed/31142473 http://dx.doi.org/10.1136/annrheumdis-2019-215039

Ejemplares similares

Leflunomide versus azathioprine for maintenance therapy of lupus nephritis: a prospective, multicentre, randomised trial and long-term follow-up
por: Fu, Qiong, et al.
Publicado: (2022)

Association of Blood Concentrations of Complement Split Product iC3b and Serum C3 With Systemic Lupus Erythematosus Disease Activity
por: Kim, Alfred H. J., et al.
Publicado: (2019)

Toll‐Like Receptor 9 Deficiency Breaks Tolerance to RNA‐Associated Antigens and Up‐Regulates Toll‐Like Receptor 7 Protein in Sle1 Mice
por: Celhar, Teja, et al.
Publicado: (2018)

Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial
por: He, Jing, et al.
Publicado: (2020)

Induction of Interferon‐γ and Tissue Inflammation by Overexpression of Eosinophil Cationic Protein in T Cells and Exosomes
por: Chuang, Huai‐Chia, et al.
Publicado: (2021)

A CD8 T Cell/Indoleamine 2,3-Dioxygenase Axis Is Required for Mesenchymal Stem Cell Suppression of Human Systemic Lupus Erythematosus
por: Wang, Dandan, et al.
Publicado: (2014)

Mitochondrial Dysfunction in the Liver and Antiphospholipid Antibody Production Precede Disease Onset and Respond to Rapamycin in Lupus‐Prone Mice
por: Oaks, Zachary, et al.
Publicado: (2016)

Longitudinal gut microbiome analyses and blooms of pathogenic strains during lupus disease flares
por: Azzouz, Doua F, et al.
Publicado: (2023)

3D genome alterations in T cells associated with disease activity of systemic lupus erythematosus
por: Zhao, Ming, et al.
Publicado: (2023)

Genomic sequencing and functional analyses identify MAP4K3/GLK germline and somatic variants associated with systemic lupus erythematosus
por: Chuang, Huai-Chia, et al.
Publicado: (2022)

Association of FCGR3A and FCGR3B Copy Number Variations With Systemic Lupus Erythematosus and Rheumatoid Arthritis in Taiwanese Patients
por: Chen, Ji-Yih, et al.
Publicado: (2014)

Gene Expression and Pharmacodynamic Changes in 1,760 Systemic Lupus Erythematosus Patients From Two Phase III Trials of BAFF Blockade With Tabalumab
por: Hoffman, Robert W., et al.
Publicado: (2017)

Belimumab use during pregnancy: a summary of birth defects and pregnancy loss from belimumab clinical trials, a pregnancy registry and postmarketing reports
por: Petri, Michelle, et al.
Publicado: (2023)

Biological impact of iberdomide in patients with active systemic lupus erythematosus
por: Lipsky, Peter E, et al.
Publicado: (2022)

Peroxisome proliferator activated receptor-γ agonist pioglitazone improves vascular and metabolic dysfunction in systemic lupus erythematosus
por: Hasni, Sarfaraz, et al.
Publicado: (2022)

Meta-analysis of 208370 East Asians identifies 113 susceptibility loci for systemic lupus erythematosus
por: Yin, Xianyong, et al.
Publicado: (2021)

Biological insights into systemic lupus erythematosus through an immune cell-specific transcriptome-wide association study
por: Yin, Xianyong, et al.
Publicado: (2022)

Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double‐Blind, Placebo‐Controlled Trials
por: Clowse, Megan E. B., et al.
Publicado: (2017)

Novel Assays of Thrombogenic Pathogenicity in the Antiphospholipid Syndrome Based on the Detection of Molecular Oxidative Modification of the Major Autoantigen β(2)-Glycoprotein I
por: Ioannou, Yiannis, et al.
Publicado: (2011)

Distinct roles for complement in glomerulonephritis and atherosclerosis revealed in mice with a combination of lupus and hyperlipidemia
por: Lewis, Myles J, et al.
Publicado: (2012)

Lack of Effect of a Single Injection of Human C-Reactive Protein on Murine Lupus or Nephrotoxic Nephritis
por: Carlucci, Francesco, et al.
Publicado: (2010)

Oxidative Stress, T Cell DNA Methylation, and Lupus
por: Li, YePeng, et al.
Publicado: (2014)

Sifalimumab, a Human Anti–Interferon-α Monoclonal Antibody, in Systemic Lupus Erythematosus: A Phase I Randomized, Controlled, Dose-Escalation Study: A Phase I Randomized, Controlled, Dose-Escalation Study
por: Petri, Michelle, et al.
Publicado: (2013)

The Parasitic Worm Product ES-62 Targets Myeloid Differentiation Factor 88–Dependent Effector Mechanisms to Suppress Antinuclear Antibody Production and Proteinuria in MRL/lpr Mice
por: Rodgers, David T, et al.
Publicado: (2015)

Dual B Cell Immunotherapy Is Superior to Individual Anti-CD20 Depletion or BAFF Blockade in Murine Models of Spontaneous or Accelerated Lupus
por: Lin, WeiYu, et al.
Publicado: (2015)

Association of Systemic Lupus Erythematosus With Decreased Immunosuppressive Potential of the IgG Glycome
por: Vučković, Frano, et al.
Publicado: (2015)

Belimumab in systemic lupus erythematosus
por: Vilas-Boas, Andreia, et al.
Publicado: (2015)

Autoantibody‐Positive Healthy Individuals Display Unique Immune Profiles That May Regulate Autoimmunity
por: Slight‐Webb, Samantha, et al.
Publicado: (2016)

Sensitivity to Change and Minimal Important Differences of the LupusQoL in Patients With Systemic Lupus Erythematosus
por: McElhone, Kathleen, et al.
Publicado: (2016)

Blockade of Interferon‐γ Normalizes Interferon‐Regulated Gene Expression and Serum CXCL10 Levels in Patients With Systemic Lupus Erythematosus
por: Welcher, Andrew A., et al.
Publicado: (2015)

What to Expect When Expecting With Systemic Lupus Erythematosus (SLE): A Population‐Based Study of Maternal and Fetal Outcomes in SLE and Pre‐SLE
por: Arkema, Elizabeth V., et al.
Publicado: (2016)

A Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Study to Evaluate the Efficacy and Safety of Treatment With Sirukumab (CNTO 136) in Patients With Active Lupus Nephritis
por: Rovin, Brad H., et al.
Publicado: (2016)

Cumulative Corticosteroid Dose Over Fifty‐Two Weeks in Patients With Systemic Lupus Erythematosus: Pooled Analyses From the Phase III Belimumab Trials
por: van Vollenhoven, Ronald F., et al.
Publicado: (2016)

Study of Flare Assessment in Systemic Lupus Erythematosus Based on Paper Patients
por: Isenberg, D., et al.
Publicado: (2017)

Brief Report: A Randomized, Double‐Blind, Parallel‐Group, Placebo‐Controlled, Multiple‐Dose Study to Evaluate AMG 557 in Patients With Systemic Lupus Erythematosus and Active Lupus Arthritis
por: Cheng, Laurence E., et al.
Publicado: (2018)

Efficacy and Safety of Atacicept in Patients With Systemic Lupus Erythematosus: Results of a Twenty‐Four–Week, Multicenter, Randomized, Double‐Blind, Placebo‐Controlled, Parallel‐Arm, Phase IIb Study
por: Merrill, Joan T., et al.
Publicado: (2018)

Efficacy and Safety of Subcutaneous Belimumab in Anti–Double‐Stranded DNA–Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus
por: Doria, A., et al.
Publicado: (2018)

Long‐Term Safety and Efficacy of Belimumab in Patients With Systemic Lupus Erythematosus: A Continuation of a Seventy‐Six–Week Phase III Parent Study in the United States
por: Furie, Richard A., et al.
Publicado: (2018)

Efficacy of Epratuzumab, an Anti‐CD22 Monoclonal IgG Antibody, in Systemic Lupus Erythematosus Patients With Associated Sjögren's Syndrome: Post Hoc Analyses From the EMBODY Trials
por: Gottenberg, Jacques‐Eric, et al.
Publicado: (2018)

REDD1/autophagy pathway promotes thromboinflammation and fibrosis in human systemic lupus erythematosus (SLE) through NETs decorated with tissue factor (TF) and interleukin-17A (IL-17A)
por: Frangou, Eleni, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ealuhlkkb1jlkmeppq36kkcm7u